12:00 AM
 | 
Oct 01, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tofacitinib: Additional Phase III data

Additional data from the double-blind, placebo-controlled Phase III ORAL Scan (1044) trial in 535 evaluable patients with moderate to severe active RA who had an inadequate response to methotrexate showed that twice-daily 5 and 10 mg oral tofacitinib plus methotrexate maintained efficacy improvements at 2 years in ACR response rates, mTSS, DAS28 score of <2.6 points and HAQ-DI scores. Specifically, ACR20 response rates at 2 years were 73.5% for low-dose tofacitinib and 82.6% for high-dose tofacitinib, while ACR50 response rates were 48.8% and 65.1%, respectively. ACR70 response rates at 2 years were 27% in the low-dose arm and 40.4% in the high-dose arm. Patients receiving low-dose...

Read the full 520 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >